Name: Latest research reports of Glenmark Pharmaceuticals Ltd. authored by Deven Choksey and published by - Trendlyne research reports.
Item: Glenmark Pharmaceuticals Ltd.
Rating: 5
Author: Deven Choksey

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296 | ISIN: INE935A01035 | Industry: Pharmaceuticals
| Mid-range Performer

1967.7000 -29.50 (-1.48%)

NSE Jan 23, 2026 15:31 PM

54.27% Gain from 52W Low

Volume: 424.2K

Glenmark Pharmaceuticals Ltd.

18 Nov 2025

1967.70

-1.48%

Exceptional Q2 buoyed by ISB-2001 income and sharp margin expansion.

Buy: Glenmark Pharmaceuticals Ltd.

Deven Choksey

We have rolled forward our valuation to Sept’27 estimates. We value Glenmark Pharma at 25.0x Sept’27 EPS implying a target price of INR 2,300.

Glenmark Pharmaceuticals Ltd. is trading above its 200 day SMA of 1837.9